1 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsDigestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, cervix disorder, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, head and neck squamous cell carcinoma, hepatocellular carcinoma, intestinal disorder, kidney cancer, kidney disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, rectal disorder, renal cell carcinoma, skin disorder, skin neoplasm, squamous cell carcinoma, stomach disorder, transitional cell carcinoma, urinary system disorder, urothelial carcinoma, uterine disorderActive, not recruitingPhase 12026-08-06NCT05581004